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Abstract
Purpose The purpose of the study is to determine the imme-
diate and long-term effect of statins on coagulation in patients
treated with vitamin K antagonists (VKAs).
Methods We selected patients on VKAs of two Dutch
anticoagulation clinics who initiated treatment with a statin
between 2009 and 2013. Patients who initiated or stopped
concomitant drugs that interact with VKAs or were
hospitalised during follow-up were excluded. The VKA dos-
age (mg/day) after statin initiation was compared with the last
VKA dosage before the statin was started. Immediate and
long-term differences in VKA dosage (at 6 and 12 weeks)
were calculated with a paired student t test.
Results Four hundred thirty-five phenprocoumon users (mean
age 70 years, 60 % men) and 303 acenocoumarol users (mean
age 69 years, 58 % men) were included. After start of statin
use, the immediate phenprocoumon dosage was 0.02 mg/day
(95 % CI, 0.00 to 0.03) lower. At 6 and 12 weeks, these
phenprocoumon dosages were 0.03 (95 % CI, 0.01 to 0.05)
and 0.07 mg/day (95 % CI, 0.04 to 0.09) lower as compared
with the dosage before first statin use. In acenocoumarol users,
VKA dosage was 0.04 mg/day (95%CI, 0.01 to 0.07) (imme-
diate effect), 0.10 (95 % CI, 0.03 to 0.16) (at 6 weeks), and
0.11 mg/day (95 % CI, 0.04 to 0.18) (after 12 weeks) lower.
Conclusions Initiation of statin treatment was associated with
an immediate and long-term minor although statistically sig-
nificant decrease in VKA dosage in both phenprocoumon and
acenocoumarol users, which suggests that statins may have
anticoagulant properties.
Keywords Hydroxymethylglutaryl-CoA reductase
inhibitors . Coumarins . Pharmacokinetics . Drug
interactions . Pharmacology
Introduction
Patients on vitamin K antagonists (VKAs) often have or de-
velop arterial cardiovascular morbidity [1], for which they
require cardiovascular drugs like statins [2]. Statins are com-
petitive inhibitors of HMG-CoA reductase that reduce choles-
terol biosynthesis [3], but may also reduce the risk of venous
thrombosis [4, 5]. However, the anticoagulant properties of
statins are not well defined and it is unclear how statins could
lower the risk of venous thrombosis [5]. Currently, three
randomised studies and one observational study have been
conducted as to observe if statins have anticoagulant proper-
ties in VKA users [2, 6–8]. These studies showed conflicting
results possibly due to the low number of participants enrolled or
because (for the observational study) of residual confounding
[2, 6–8]. In addition, it is unclear whether potential anticoagulant
properties of statins in VKA users are due to drug-drug interac-
tions with VKA or due to pharmacodynamic effects of the
statins. To gain more insight into the effects of statins on coagu-
lation in VKA users, we compared coagulation of patients on
VKAs before and up till 12 weeks after starting statin therapy.
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Methods
Study design, patient selection, and data collection
Patients’ characteristics and outcomes were collected from the
computerised records of the anticoagulation clinic Leiden and
the Star-Medical Diagnostic Center, Rotterdam. At these
anticoagulation clinics, all patients are monitored at least every
6 weeks. At each visit, a standard questionnaire is performed
regarding initiation of concomitant medications and planned
procedures after which blood is drawn to determine the inter-
national normalised ratio (INR). Based on the INR, the VKA
dosage until the next visit is set by a trained physician at the
anticoagulation clinic.
All patients, who started treatment with VKAs (i.e.
phenprocoumon or acenocoumarol) between January
2009 and December 2013, were screened. This time
period was chosen as the coded registration of statin
treatment in our databases started in 2009. Patients were
included who started to use a statin within this period.
Patients were excluded if they started to use inegy
(combination of ezetimibe and simvastatin) because it
is unknown to which degree both medications are attrib-
utable to a possible anticoagulant effect. Patients who
were already using statins at baseline or started to use
a statin within the first 2 months of VKA treatment
were also excluded. Patients were excluded when they
were hospitalised between the INR measurement before
and after statin initiation because for example an acute
myocardial infarction may affect coagulation and there-
fore change the outcome (INR and dosage of VKA).
Patients were also excluded if they started or stopped
any interacting medication with VKAs, according to the
national list of medication interacting with VKA of
Dutch Anticoagulation Clinics [9], during their individ-
ual observation period within this study. Neither in-
formed consent nor approval by a medical ethics com-
mittee is, according to Dutch law, required for studies in
which data are collected from the records by the
treating physician.
Outcome measures
INR and dosage of VKAs were determined on the last visit
before and the first visit after start of statin use to assess an
immediate anticoagulant effect. We determined the immediate
difference in INR as this reflects the amount of coagulation at
a particular time point. The immediate change in dosage of
phenprocoumon or acenocoumarol after first statin use was
expected to decrease if statins would increase the INR as
VKA dosage is based on INR results. To study the long-
term effect of statins on coagulation, the VKA dosage 6 and
12 weeks after statin initiation was compared with the last
dosage before statin initiation. If no INRwas available at these
exact dates, the INR closest to the specific date of statin initi-
ation was chosen. The differences in INR and dosage were
also expressed in percentages.
Statistical analysis
Data for continuous variables are expressed as means with
standard deviations (SDs), and categorical data are
expressed as numbers with percentages. In this study, pa-
tients are compared with themselves (cross-over analysis).
Therefore, the mean difference in INR and VKA dosage
with 95 % CI was estimated by means of linear regression
and was adjusted for study centre. The reference category
in all analyses was the INR and VKA dosage at the last
known date before first statin use. All statistical analyses
were performed with R version 3.1.1.
Results
Clinical characteristics
Thirty-two thousand, two hundred ninety patients used VKAs
between 2009 and 2013, of which 12,074 used phenpro
coumon and 20,216 used acenocoumarol. Of these VKA
users, 1273 and 792 initiated a statin during VKA treatment,
respectively. Statin initiators who were not admitted to a hos-
pital and did not initiate or stop drugs that interact with VKAs
during the study period were included for the analysis,
resulting in 435 and 303 statin initiators on phenprocoumon
and acenocoumarol, respectively.
The mean age of the patients was 70 years (± standard
deviation 10) when starting statin therapy (Table 1). The most
common indication for VKAs was atrial fibrillation (n = 537,
73%) and 438 patients (59%) were male. Simvastatin was the
most initiated statin (n = 516, 70 %), while rosuvastatin was
not initiated among phenprocoumon users in this sample. One
patient started fluvastatin therapy among the phenprocoumon
as well as among acenocoumarol users. Clinical characteris-
tics were similar in acenocoumarol and phenprocoumon users
and all patients kept the same INR target range during the
study period.
Immediate INR and dosage change
Table 2 shows the INRs and mean VKA dose immediately
after starting statin treatment in phenprocoumon and
acenocoumarol users. After starting statin treatment, patients
had an appointment at the anticoagulation clinic after on av-
erage 1 week. The immediate average INR increase in
phenprocoumon users was 0.10 (95 % CI 0.04 to 0.17) or
6 % (95 % CI 3 to 8 %). In acenocoumarol users, no
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immediate change in INR was observed (INR 0.02 [95 % CI
−0.10 to 0.14] increased). The mean difference of daily dos-
age of phenprocoumon users was 0.02 mg per day (95 % CI
0.00 to 0.03) lower and for acenocoumarol users 0.04 mg per
day (95 % CI 0.01 to 0.07) lower. Stratification by statin type
showed that both INR changes and dose changes were similar
between the different types of statins.
Long-term dosage change
Table 3 shows the long-term change in VKA dosage after initi-
ating statin therapy in acenocoumarol and phenprocoumon users.
The mean difference in daily dosage of phenprocoumon users
was 0.03 mg/day (95%CI 0.01 to 0.05) lower after 6 weeks and
0.07 mg/day (95 % CI 0.04 to 0.09) lower after 12 weeks. The
mean difference in daily dosage of acenocoumarol users was
0.10 mg/day (95 % CI 0.03 to 0.16) lower after 6 weeks and
0.11 mg/day (95 % CI 0.04 to 0.18) lower after 12 weeks. After
analyses were stratified by statin type, it appeared that a stronger
decrease of VKA dosage was present in simvastatin (among
acenocoumarol and phenprocoumon users) and rosuvastatin
users (among acenocoumarol users) as compared with the other
types of statins.
Discussion
The current study investigated the effect on anticoagulant
properties within 738 patients on VKA therapy who initi-
ated statins. Results on immediate INR differences showed
that the INR increased slightly in phenprocoumon users but
not in acenocoumarol users. The effect of initiating statin
treatment on the INR was also investigated in two
randomised studies in healthy volunteers [2, 6]. The study
from Yu Cu et al. showed an INR increase of 0.16 9 days
after rosuvastatin initiation [2], and the study by Jindal
et al. found no INR difference 7 days after rosuvastatin
initiation [6]. The results of our study confirm the results
of these trials where the immediate INR increase was also
close to null. In addition, the VKA dosage decreased in
both phenprocoumon and acenocoumarol users which be-
came apparent for both VKAs after 6 to 12 weeks. The
results showed that initiating statin treatment is associated
with a decrease of VKA dosage after 6 and 12 weeks,
which suggests that statins interact with VKAs or have
anticoagulant properties.
A potential explanation for the decrease of VKA dosage
in statin users is confounding. However, we did take con-
founding into account, as we compared patients with them-
selves in which, confounding by fixed (constant) character-
istics (e.g. diabetes mellitus, hypertension and genetics) is
eliminated. At the time that this study was conducted, INR
target ranges in the Netherlands were higher as compared
to international guidelines. Because patients are compared
with themselves and the INR target range stayed the same
during the study period, INR target range could not have
confounded our results. However, transient risk factors can
introduce (non-fixed) confounding [10]. For example, one
non-fixed confounding factor is the initiation of concomi-
tant medication or experiencing a cardiovascular event
(e.g., a myocardial infarction). To avoid this type of non-
fixed confounding, we excluded all patients who started or
stopped medications that interact with VKAs during the
study period or were admitted to the hospital. Another
non-fixed confounding factor is an acute transient disease,
for example fever [11]. However, such a transient disease is
unlikely to explain the long-term (6–12 weeks) effect that
statins had on the VKA dosage in our study. A further
possibility for the decrease in VKA dosage that we found
after statin was initiated is that statins interact with VKAs.
Acenocoumarol and phenprocoumon are racemic mixtures
where the enantiomer largely responsible for the anticoagulant
effect are metabolised by CYP3A4 and CYP2C9 [12].
Stratification by type of statin showed that rosuvastatin and sim-
vastatin were associated with the strongest decrease in VKA
dosage. Rosuvastatin is only 10 % metabolised by CYP2C9,
while simvastatin is metabolised by CYP3A4 [13]. The dosage
decrease after initiation of rosuvastatin, which is hardly
Table 1 Clinical characteristics
Phenprocoumon Acenocoumarol
Patients 435 303
Age 70 (10) 69 (11)
Men 262 (60) 176 (58)
Indication phenprocoumon treatmenta
Atrial fibrillation 337 (78) 200 (66)
Venous thrombosis 53 (12) 34 (11)
Mechanical heart valves 13 (3) 24 (8)
Vascular surgery 13 (3) 10 (3)
Ischemic heart disease 20 (5) 23 (8)
Other 12 (3) 1 (0)
Target range INR
2.5–3.5 404 (93) 242 (80)
3.0–4.0 31 (7) 61 (20)
Type of statin used
Simvastatin 310 (71) 206 (68)
Atorvastatin 60 (14) 51 (17)
Pravastatin 64 (15) 17 (6)
Rosuvastatin 0 (0) 28 (9)
Fluvastatin 1 (0) 1 (0)
Continuous variables denoted as mean (standard deviation), categorical
variables as number (%)
a Numbers do not add up to 100 % as patients may have multiple indica-
tions for VKA treatment
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metabolised by CYP2C9, suggests that our results are not likely
to be explained by drug-drug interactions. In addition, differences
in lipophilicity of statins are also unlikely to account for the
differences found between statins as rosuvastatin is hydrophilic
while simvastatin is lipophilic. A potential other explanation is
that statins do reduce coagulation, which was suggested by
Sahebkar et al. because D-dimer levels decreased after 3 months
of statin therapy and because D-dimer levels are markers of
coagulation [14]. To get more insight whether simvastatin and
rosuvastatin have anticoagulant properties, a next step would be
to investigate the effect of these statins on coagulation in patients
not on VKAs.
Though the current study is of etiological interest as
it gives a lead why statins might be able to decrease
venous thrombosis risk, its clinical effect appears to be
minimal: INRs did not increase immediately and only
marginally, and the VKA dose reduction was also
minimal.
A potential limitation of our study is that co-medication
was self-reported and the only statin reported by the phar-
macy to the anticoagulation clinics was rosuvastatin.
Consequently, there may be discrepancies between the
medication records of the anticoagulation clinics and what
the patients used. As patients were compared with them-
selves, we expect that this has not influenced the results.
An additional limitation is that we excluded patients who were
hospitalised between the INRmeasurement before and after stat-
in initiation.We did this because the assumption of the study, that
there are no other environmental changes present that can affect
VKA dosage and/or INR in the patient except that the patient
started with statin, is otherwise not held. For that reason, we
could have missed patients of more ‘dramatic’ changes of
anticoagulation, like patients with a major bleed. Furthermore,
pharmacokinetics of the two studied VKAs do differ, for exam-
ple phenprocoumon has a longer half-life as compared with
acenocoumarol [12]. However, differences in pharmacokinetics
of the VKAs tested are unlikely to have contributed to the statin
results found in this study as results were similar in both
acenocoumarol and phenprocoumon users. Another limitation
is that we assumed that patients are compliant to their statin
therapy. It is likely that not all patients were fully compliant as
previous studies showed an average adherence to statins of 71–
77 % [15]. Our results could therefore be diluted and the effects
on VKA dosage are likely to be stronger if we could have taken
statin adherence into close account. A final limitation of our
study is that the dosage of statins was not registered in the elec-
tronic system. Therefore, no analyses could be performed that
took the dosage of statin into account.
In conclusion, we found that statin treatment was associat-
ed with a minor although statistically significant decrease in
VKA dosage in both phenprocoumon and acenocoumarol
users, which suggests that statins may have anticoagulant
properties.
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